Blastic Plasmacytoid Dendritic Cell Neoplasm With Leukemic Progression

Choladda V. Curry\textsuperscript{a}, Sergej N. Konoplev\textsuperscript{b}, Carlos Torres-Cabala\textsuperscript{c,d}, Amin Alousi\textsuperscript{e}, Madeleine Duvic\textsuperscript{c}, Jonathan L. Curry\textsuperscript{c,d,f}

Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDN), previously described as blastic NK cell lymphoma and CD4+/CD56+ hematodermic neoplasm, is an aggressive hematologic malignancy with poor prognosis. We report a patient with BPDN who developed multiple recurrences and eventually leukemic progression. The patient died of disease 31 months after initial diagnosis. Long term survival for BPDN is poor despite multiple regimens of chemotherapy and bone marrow stem cell transplant.

Keywords: Blastic Plasmacytoid dendritic cell neoplasm; Blastic NK cell lymphoma; CD4+/CD56+ hematodermic neoplasm; Leukemia; Stem cell transplant

Case Report
A 66-year-old male presented with a 3 cm elevated, violaceous nodule on the back for 3 months duration without resolution. Biopsy examination of the nodule demonstrated a dense hematolymphoid infiltrate composed of blastic appearing neoplastic cells involving the dermis and superficial portion of the subcutaneous tissue. The epidermis was not involved and was separated by a narrow Grenz zone. The neoplastic cells were reactive for CD4, CD56 and CD45RA and negative for CD20, CD3, CD8, TdT, CD34, and CD117. A diagnosis of cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN) was rendered, and the nodule was excised. Staging studies with CT scan and PET/CT scan showed neither lymphadenopathy nor FDG-avid lesions. A month later, the patient continued to develop multiple purple to brown, bruise like macules and papules on his chest, back, extremities and face (Fig. 1A). The skin punch biopsy of right upper back shows a monotonous infiltrate of neoplastic cells of similar cytomorphology to the previous biopsies, primarily distributed in a perivascular and periadnexal pattern (Fig. 1B-C). Immunohistochemically (IHC), neoplastic cells were positive for CD4, CD56, CD123, and TCL-1 (Fig. 1D-F), and are negative for CD3, CD8 and CD20.

The patient was subsequently treated with four cycles of hyper CV AD alternating with methotrexate and cytarabine which resulted in reduction and disappearance of his skin lesions. The patient remained in remission. Nineteen months after initial presentation, PET scan demonstrated a new hypometabolic cutaneous mass on the left lower leg and biopsy confirmed recurrence of disease. Bilateral bone marrow biopsy was negative for neoplasm. Patient was treated with six cycles of pralatrexate and during his second complete remission underwent autologous peripheral blood stem cell transplant with BEAM (carmustine (BCNU), etoposide, Ara-C (cytarabine), and melphalan) conditioning. He remained without evidence of cutaneous disease at 160 days status post autologous stem cell transplant when he developed pancytopenia which prompted bone marrow biopsy that demonstrated progression to acute leukemia with 77\% blasts along with circulating blasts in peripheral blood at 30 months since initial diagnosis of BPDN (Fig. 1G, H). By flow cytometric analysis, blasts were positive for CD4, CD7 (dim), CD56, CD33, CD117, HLA-DR, and TdT (partial) and negative for CD2, CD3, CD5, CD8, CD34, and myeloperoxidase. Leukemic cells were positive for CD123 by IHC (Fig. 1I). The patient died of disease 31 months after initial diagnosis.

\textsuperscript{a}Department of Pathology, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas, U.S.A.
\textsuperscript{b}Departments of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
\textsuperscript{c}Departments of Pathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
\textsuperscript{d}Departments of Dermatology, the University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
\textsuperscript{e}Departments of Stem Cell Transplantation, the University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.

Corresponding author: Jonathan L. Curry, Department of Pathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A. Email: jlcurry@mdanderson.org

doi: http://dx.doi.org/10.4021/jmc829w
Discussion

Blastic plasmacytoid dendritic cell neoplasm, previously described as blastic NK cell lymphoma and CD4+/CD56+ hematodermic neoplasm is an aggressive hematologic malignancy with poor prognosis [1-3]. The CD4+/CD56+ neoplastic cells demonstrate differentiation towards the plasma cytoid type 2 dendritic cell (DC2) and therefore also express CD123 and lymphoid proto-oncogene TCL1 [4]. One third of the cases are TdT positive [1]. Lesions may be localized or present as generalized tumors and plaques with bruise-like violaceous appearance. Bone marrow involvement is known to occur often with leukemic progression of advanced or relapsed disease [5, 6]. Response to systemic chemotherapy with short period of remissions followed by recurrence is typical. Long term survival is dismal with conventional therapy and bone marrow stem cell transplantation should be considered as therapeutic option [7, 8].

Grant Support

Not applicable.

References

3. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Ver-
Blastic Plasmacytoid Dendritic Cell Neoplasm


